Skip to main content

Table 1 Weight gain, and blood and serum parameters after 8 weeks of treatment in control and diabetic mice

From: SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart

 

Con (n = 15)

DM (n = 15)

DM + EM (n = 15)

P value

Body weight (g)

25.46 ± 0.70

33.61 ± 1.40*

32.17 ± 1.23*

< 0.001

Body weight gain (g)

5.32 ± 0.64

8.05 ± 0.64*

6.61 ± 0.42*#

< 0.001

Heart weight (mg)

130.45 ± 5.81

152.37 ± 6.26*

149.13 ± 7.87*

< 0.001

Heart weight/Tibial length (mg/mm)

7.73 ± 0.25

8.72 ± 0.32*

8.42 ± 0.27*

< 0.001

Blood glucose (mmol/L, fasting)

6.38 ± 0.27

18.83 ± 1.17*

9.27 ± 0.76*#

< 0.001

Blood glucose (mmol/L, non-fasting)

8.26 ± 0.38

26.39 ± 1.38*

12.51 ± 1.08*#

< 0.001

HbA1c (mmol/mol)

22.93 ± 2.82

94.71 ± 6.52*

39.57 ± 4.95*#

< 0.001

Insulin (μg/L)

1.71 ± 0.22

4.92 ± 0.43*

2.69 ± 0.51*#

< 0.001

TC (mg/dL)

87.59 ± 3.66

215.89 ± 14.08*

216.35 ± 15.67*

< 0.001

HDL-C (mg/dL)

32.76 ± 2.29

73.16 ± 6.51*

75.71 ± 4.71*

< 0.001

LDL-C (mg/dL)

40.59 ± 4.92

63.54 ± 6.35*

62.12 ± 5.96*

< 0.001

TG (mg/dL)

94.24 ± 6.25

314.87 ± 24.10*

310.47 ± 25.67*

< 0.001

  1. Data are expressed as the mean ± SD
  2. TC total cholesterol, TG triglyceride, HDL-C high-density lipoprotein, LDL-C low-density lipoprotein
  3. *P < 0.05 vs. Con; #P < 0.05 vs. DM